In the blast cell population, we found AML patient-1 to have a 2-fold increase in intensity of FLT3 expression during therapy and AML patient-2 to have a 1.6-fold increase (AML patient-1 at diagnosis having calculated raw value of FLT3 median: 2.78 and at D3 increased to: 5.57; AML patient-2 at diagnosis: 0 and D3: 1.63). Here, FLT3 is linked to acute myeloid leukemia.